Clearside Biomedical, Inc.
CLSDNASDAQHealthcare
$0.41
+$0.00(+0.00%)
Market Cap$2145948
P/E Ratio—
52W High$17.1
52W Low$0.31
Clearside Biomedical, Inc. (CLSD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CLSD · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2025Report Date: Nov 14, 2025EPS Actual
-$1.14
Est. -$0.67 · -70.2%
Revenue
$0.00B
Est. $0.00B · -36.5%
Fiscal Period
Q4 FY2025
FY ends December
Report Date
Nov 14, 2025
After Market Close
▼ Miss EPS▼ Miss Revenue
CLSD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.00
Rev. $1.80B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.00
Rev. Est.$1.80B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | May 12, 2026 | — | — | — | — | — | — |
| ◌ Q1 FY2026 | Mar 20, 2026 | -$0.60 | — | — | — | $0.00B | — |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$0.67 | -$1.14 | -70.2% | $0.00B | $0.00B | -36.5% |
| ▲ Q3 FY2025 | Aug 8, 2025 | -$1.80 | -$0.90 | +50.0% | $0.00B | $0.00B | +459.1% |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.12 | -$0.11 | +8.3% | $0.00B | $0.00B | +1077.8% |
| ▲ Q1 FY2025 | Mar 27, 2025 | -$0.13 | -$0.10 | +23.1% | $0.00B | $0.00B | +3.9% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.14 | -$0.10 | +28.6% | $0.00B | $0.00B | +252.6% |
| ▲ Q3 FY2024 | Aug 12, 2024 | -$0.14 | -$0.10 | +28.6% | $0.00B | $0.00B | -40.0% |
Q2 FY2026
May 12, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 20, 2026
EPS Actual
—
EPS Est.
-$0.60
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$1.14
EPS Est.
-$0.67
EPS Surpr.
-70.2%
Revenue
$0.00B
Q3 FY2025
Aug 8, 2025Beat
EPS Actual
-$0.90
EPS Est.
-$1.80
EPS Surpr.
+50.0%
Revenue
$0.00B
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.11
EPS Est.
-$0.12
EPS Surpr.
+8.3%
Revenue
$0.00B
Q1 FY2025
Mar 27, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.13
EPS Surpr.
+23.1%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.10
EPS Est.
-$0.14
EPS Surpr.
+28.6%
Revenue
$0.00B
Q3 FY2024
Aug 12, 2024Beat
EPS Actual
-$0.10
EPS Est.
-$0.14
EPS Surpr.
+28.6%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-1.20 | $-1.20 | $-1.20 | 1 |
| Q3 FY2026 | $-1.20 | $-1.20 | $-1.20 | 1 |
| Q2 FY2026 | $-1.35 | $-1.35 | $-1.35 | 1 |
| Q1 FY2026 | $-1.35 | $-1.35 | $-1.35 | 1 |
| Q4 FY2025 | $-0.60 | $-0.60 | $-0.60 | 1 |
| Q3 FY2025 | $-0.83 | $-0.62 | $-0.42 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2025 | Nov 14, 2025 | -70.2% | $3.69 | $3.82 | +3.52% |
| ▲ Q3 FY2025 | Aug 8, 2025 | +50.0% | $5.75 | $6.11 | +6.26% |
| ▲ Q2 FY2025 | May 14, 2025 | +8.3% | $13.50 | $12.81 | -5.11% |
| ▲ Q1 FY2025 | Mar 27, 2025 | +23.1% | $15.30 | $15.45 | +0.98% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +28.6% | $16.35 | $16.65 | +1.83% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +28.6% | $16.35 | $16.05 | -1.83% |
| ▼ Q2 FY2024 | May 9, 2024 | -21.4% | $19.05 | $20.25 | +6.30% |
| ▲ Q1 FY2024 | Mar 12, 2024 | +20.0% | $30.30 | $24.60 | -18.81% |
Q4 FY2025+3.52%
Report Date
Nov 14, 2025
EPS Beat/Miss
-70.2%
Price Before
$3.69
Price After
$3.82
Q3 FY2025+6.26%
Report Date
Aug 8, 2025
EPS Beat/Miss
+50.0%
Price Before
$5.75
Price After
$6.11
Q2 FY2025-5.11%
Report Date
May 14, 2025
EPS Beat/Miss
+8.3%
Price Before
$13.50
Price After
$12.81
Q1 FY2025+0.98%
Report Date
Mar 27, 2025
EPS Beat/Miss
+23.1%
Price Before
$15.30
Price After
$15.45
Q4 FY2024+1.83%
Report Date
Nov 12, 2024
EPS Beat/Miss
+28.6%
Price Before
$16.35
Price After
$16.65
Q3 FY2024-1.83%
Report Date
Aug 12, 2024
EPS Beat/Miss
+28.6%
Price Before
$16.35
Price After
$16.05
Q2 FY2024+6.30%
Report Date
May 9, 2024
EPS Beat/Miss
-21.4%
Price Before
$19.05
Price After
$20.25
Q1 FY2024-18.81%
Report Date
Mar 12, 2024
EPS Beat/Miss
+20.0%
Price Before
$30.30
Price After
$24.60
Avg Beat Reaction-2.78%
Avg Miss Reaction+4.91%
Beat Rate6 / 8 quarters
Largest Move-18.81% (Q1 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CLSD ends December
Clearside Biomedical, Inc. (CLSD) most recently reported earnings on November 14, 2025 for Q4 FY2025, posting EPS of $-1.14 — missing the analyst consensus of $-0.67 by -70.2%. The next CLSD earnings date is expected around September 1, 2026.
Each quarter, investors track CLSD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CLSD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CLSD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CLSD earnings · 5 questionsClearside Biomedical, Inc.'s next earnings report is expected around September 1, 2026. CLSD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CLSD historically reports after market close (AMC).
CLSD earnings datewhen is CLSD earningsCLSD next earnings datewhen does CLSD report earningsCLSD earnings calendar
▸ Source: FMP · Clearside Biomedical, Inc. SEC filings · US GAAP · Clearside Biomedical, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026